The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma

Introduction Cabozantinib is an oral tyrosine kinase inhibitor that is approved for the treatment of metastatic renal cell carcinoma (mRCC). Cabozantinib is a weak base that exhibits a pH‐dependent solubility profile in vitro which raises concerns about its bioavailability in patients treated with p...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2021-05, Vol.26 (5), p.389-396
Hauptverfasser:	Rassy, Elie, Cerbone, Luigi, Auclin, Edouard, Benchimoll‐Zouari, Axelle, Flippot, Ronan, Alves Costa Silva, Carolina, Colomba, Emeline, Geraud, Arthur, Guida, Annalisa, Mir, Olivier, Combarel, David, Paci, Angelo, Escudier, Bernard, Albiges, Laurence
Format:	Artikel
Sprache:	eng
Schlagworte:	Cabozantinib Carcinoma, Renal cell Care and treatment Development and progression Diagnosis Dosage and administration Genitourinary Cancer Metastasis Overall survival Pharmacology Proton pump inhibitors Renal cell carcinoma Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!